Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health (NASDAQ:COSM) announced on October 10, 2025 that it purchased an additional $500,000 of Ethereum (ETH), bringing its total ETH holdings to $1.5 million. The purchase was executed under the company’s existing $300 million digital assets facility as part of a balance-sheet diversification strategy and to explore blockchain-enabled healthcare solutions. Management reiterated intent to continue using the financing facility and described digital assets as both long-term investments and potential enablers of decentralized healthcare applications.

Cosmos Health (NASDAQ:COSM) announced that subsidiary SkyPharm S.A. signed an exclusive distribution agreement dated September 28, 2025 with Diyar United to market and sell Sky Premium Life® nutraceuticals in Kuwait. Diyar United will manage registration, promotion, logistics and distribution for formulations including collagen, hyaluronic acid, vitamins B/C/D3+K2, magnesium, zinc, turmeric, maca, rhodiola, multivitamins and hair/skin/nail blends. Cosmos secured an initial purchase order of over 65,000 units, with further orders expected as the sales pipeline develops. The PR cites Kuwait’s supplements market at $1.16B in 2024, projected to $1.68B by 2030 (CAGR ~6.3%).

Cosmos Health (NASDAQ:COSM) CEO Greg Siokas outlined the company's transformation into a global healthcare powerhouse, highlighting several major developments. The company secured a $300 million digital financing facility, with 72.5% allocated to building a digital treasury reserve in cryptocurrencies and the remainder for working capital and growth initiatives.

Key achievements include: expansion of U.S. manufacturing operations through NOOR Collagen partnership, significant growth of Sky Premium Life brand across multiple international markets, and record performance from CosmoFarm wholesale division with $43 million revenue in first 10 months of 2024. The company's Cana Laboratories secured major contracts, including a 10-year agreement for 8 million packs with Provident Pharmaceuticals.

The company advanced its R&D pipeline, particularly with obesity treatment CCX0722, and expanded its portfolio through acquisitions and partnerships in pharmaceuticals and diagnostics.

Cosmos Health (NASDAQ:COSM) has announced that its subsidiary Cana Laboratories has secured a contract manufacturing agreement with Medical Pharmaquality S.A. for the production of MYCOFAGYL® pessaries. The agreement entails manufacturing 3 million pessaries annually, packaged in 10-unit sets.

MYCOFAGYL® combines Metronidazole (500mg) and Nystatin (100,000 IU) to treat vaginal infections, including bacterial vaginosis and candidiasis. This expansion into gynecological products represents a strategic diversification of Cana's manufacturing portfolio and strengthens its position in the European pharmaceutical market.

Cosmos Health (NASDAQ:COSM) has launched its U.S. operations by introducing its Sky Premium Life food supplements brand, marking its entry into the $164B U.S. nutraceuticals market. The company's first product, NOOR Collagen, is manufactured in FDA-registered, GMP-certified U.S. facilities.

The company projects 75% gross margins and expects NOOR Collagen alone to generate over $12M in annualized revenue. The U.S. nutraceuticals market is forecasted to grow at a 6.2% CAGR through 2030, driven by increasing health awareness and demand for natural wellness solutions.

This strategic expansion includes local manufacturing to mitigate tariff exposure and logistical risks, with plans for additional product launches to meet U.S. consumer demand.

Cosmos Health (NASDAQ:COSM) has signed a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplements in Oman. The deal includes an initial purchase order of 42,000 units and marks COSM's strategic entry into the GCC nutraceuticals market, valued at $6.91 billion in 2024.

Scientific Pharmacy, owned by Gulf Pharmaceutical Industries (Julphar), will manage regulatory compliance, product registration, distribution, marketing, and retail sales through its established network. The GCC nutraceuticals market is projected to reach $15.5 billion by 2033, growing at a CAGR of 8.7%, driven by increasing health awareness and higher disposable incomes.

Cosmos Health (NASDAQ:COSM) reported strong Q2 2025 financial results, with revenue increasing 11.7% to $14.75 million compared to Q2 2024. The company demonstrated significant improvements in profitability metrics, with gross profit surging 51.6% to $1.16 million and gross margin expanding by 208 basis points to 7.89%.

For H1 2025, revenue reached $28.46 million, up 2.4% year-over-year, while gross profit rose 53% to $3.21 million. The company's balance sheet strengthened with total assets growing 13.9% to $61.84 million and stockholders' equity increasing to $26.23 million. Additionally, Cosmos secured a significant $300 million financing facility for digital asset investments, marking its entry into the crypto space with initial Ethereum purchases.

Cosmos Health (NASDAQ:COSM) has initiated its digital asset treasury strategy with a $1 million purchase of Ethereum (ETH). This investment is part of a larger $300 million financing facility secured with a U.S.-based institutional investor.

CEO Greg Siokas explained that this strategic move aims to diversify the company's balance sheet beyond cash holdings, citing ETH's potential appreciation and growing institutional adoption through ETFs, retirement plans, and enterprise applications.

Cosmos Health (NASDAQ:COSM) has secured a significant financing facility of up to $300 million through senior secured convertible promissory notes to launch an Ethereum (ETH) treasury strategy. The agreement, made with a U.S.-based institutional investor, requires the company to allocate at least 72.5% of net proceeds toward building its digital asset treasury reserve.

The initiative includes ETH custody and staking through BitGo Trust Company, with plans to explore blockchain applications in supply chain traceability and wellness programs. The remaining funds will support working capital needs, product development, R&D innovation, and the company's planned expansion into U.S. manufacturing.